Liver – GREEN SUGR

Study: History of Marijuana Use Not Associated with Increased Heart Attack Risk

Posted on February 21, 2022February 21, 2022 by dylanramsey

Source: Norml.org | Author: Norml | Feb 17, 2022

New York, NY: Cannabis smoke exposure is not positively associated with an increased risk of myocardial infarction, according to data published in the journal Cureus.

A pair of researchers with the Icahn School of Medicine at Mount Sinai in New York City assessed the association between a history of cannabis smoking and heart attack in a cohort of over 500,000 subjects from the United Kingdom.

Researchers identified an inverse association between cannabis use and incidences of myocardial infarction, and they found no correlation between marijuana consumption and heart attack severity.

“With marijuana use, MI [myocardial infarction] decreased,” authors concluded. They further acknowledged: “The association of marijuana use with reduced risk of MI is not entirely in accord with current assumptions about the cardiac effects of marijuana. … Further studies are warranted.”

Studies assessing the association between cannabis use and cardiovascular health have been inconsistent, with some studies finding an increased risk of stroke and other cardiovascular diseases among marijuana consumers while others report either no risk or provide evidence of possible cardioprotection.

Full text of the study, “Marijuana and myocardial infarction in the UK Biobank cohort,” appears in Cureus.

Clinical Study Reports No Evidence of Liver Toxicity in CBD

Posted on March 24, 2021February 21, 2022 by dylanramsey

Source: Hemp Supporter | Author: Hemp Supporter | Mar 24, 2021

We’re excited to announce the results of an important clinical study conducted by ValidCare on CBD: Preliminary results reveal no evidence of liver toxicity.

Since passage of the 2018 Farm Bill, the FDA has been investigating a pathway to regulate the sale of ingestible hemp-derived CBD products. Unfortunately, the agency has not taken any concrete steps, claiming that it needs more real-world data on CBD’s safety profile.

As part of the hemp industry’s continuing effort to provide FDA data, ValidCare commissioned a study and concluded that “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions.”

Major kudos to ValidCare, as well as to the US Hemp Roundtable members who funded and participated in the study: American Shaman, CBD Distillery, Charlotte’s Web, Hemp Fusion, Kannaway and Medterra.

Evidence like this confirms that it is high time for FDA to legally recognize and regulate ingestible hemp-derived CBD products. That’s why it’s so important that Congress pass HR 841, which would establish a legal pathway for the sale of hemp-derived extracts as dietary supplements.

Please use our online portal to email your U.S. Representative today, urging him or her to co-sponsor HR 841.